OVERVIEW

Medical Crossfire®: Exploring the Latest Advancements in Prostate Cancer Care is organized by Physicians' Education Resource, LLC (PER).

Release Date: January 31, 2020
Expiration Date: January 31, 2021

Accreditation:
The University of Cincinnati designates this enduring material for a maximum 1.5 AMA PRA Category 1 Credits™.

Activity Overview:
In the past decade, the treatment armamentarium for advanced/metastatic, hormone-naïve, and castration-resistant prostate cancer (CRPC) has expanded dramatically, providing more choices and greater potential to improve clinical outcomes but also increasing the complexity of decision making in the clinic. The available agents have different mechanisms of action and different safety profiles and lead to different clinical outcomes. In this Medical Crossfire® activity, the expert panel will discuss the latest data regarding current and emerging therapeutic strategies for the management of prostate cancer across lines of care. A case-based, lively discussion will help place new developments into clinical context to help you optimize care for your patients with prostate cancer.

Benefits of Participating:
• Hear the latest updates on emerging strategies for the care of your patients with prostate cancer
• Contextualize emerging data through challenging case-based scenarios across lines of care in prostate cancer
• Benefit from discussion on how the experts best apply advances in the field of prostate cancer to manage the disease in their patients
• Gain expert perspective on future directions in prostate cancer care

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Describe emerging therapeutic options in prostate cancer across multiple patient populations and lines of care
• Integrate novel clinical evidence into clinical practice to optimize the clinical outcomes of patients with prostate cancer
• Optimize treatment sequences using novel agents for the treatment of patients with prostate cancer
• Define strategies to proactively identify and mitigate adverse events associated with different prostate cancer treatment options